Safety scare knocks Novartis
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
To challenge Ocrevus, German Merck takes on Aubagio
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Crunch time for the new Parkinson’s hopes
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Asco-GU: confirmation for Seattle and a reminder for Mirati
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
Biopharma’s big bet on cancer is laid bare
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Asco-GU 2020: revving up for Peloton deal validation
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
Perioperative use proves elusive for Tecentriq
Adjuvant and neoadjuvant settings are an important target for Roche’s Tecentriq, but how likely is the drug to become broadly applicable?
Another Alzheimer’s failure for Biogen bulls to shrug off
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.